- Trial phase
- Phase 2 (registration-intent) with Phase 3 confirmatory trial initiated
- Time to market
- If the DENALI Part 2 readout in 1H 2027 is positive, Zentalis plans to discuss an accelerated approval pathway with the FDA in 2027. Under an accelerated approval scenario, a potential FDA decision could come in 2028 at the earliest, though the timeline is uncertain and depends on regulatory feedback.
- Why 8/10
- The next hard, dated catalyst is the DENALI Part 2 topline readout expected in 1H 2027 (roughly 2-7 months from today). This is a pivotal Phase 2 readout that could support an accelerated approval filing for azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer. Zentalis is essentially a single-asset company, making this a make-or-break binary event.
The next major catalyst is the DENALI Part 2 topline readout expected in 1H 2027 (roughly 2-7 months away). A positive readout could support an accelerated approval filing with the FDA; a negative or mixed readout would likely devastate the stock given Zentalis is a single-asset company. The August 2026 delay from year-end 2026 to 1H 2027 was a negative signal, and the stock now trades at $1.74, well below the $3.50 August offering price. Monitor FDA discussions in 2027 and any pre-readout data disclosures.
Price Chart
Executive Summary
Azenosertib is Zentalis Pharmaceuticals' lead and only late-stage drug candidate, an oral WEE1 inhibitor being developed primarily for Cyclin E1-positive platinum-resistant ovarian cancer (PROC). The drug has FDA Fast Track designation and recently showed promising overall survival data at ESMO 2026 (15.9 months median OS in the biomarker-positive subgroup vs 7.5 months in the negative subgroup). The pivotal DENALI Part 2 topline readout, which could support an accelerated approval filing, is expected in 1H 2027 (delayed from year-end 2026). Zentalis is a single-asset, pre-revenue biotech with a $163M market cap, trading at $1.74, well below its $3.50 August 2026 offering price. The stock offers a high-risk/high-reward binary setup around the upcoming readout, with strong analyst support (mean PT $7.33) but significant dilution and timeline risk.
How It Works
Azenosertib is a WEE1 inhibitor, an oral pill that blocks a protein called WEE1 which acts as a quality-control checkpoint for cell division. Cancer cells often have damaged DNA that they cannot repair properly, but they rely on WEE1 to pause cell division long enough to fix the damage. By blocking WEE1, azenosertib forces cancer cells to divide before they can repair their DNA, causing them to die. This approach is particularly effective in cancers with high levels of Cyclin E1, a protein that makes cancer cells even more dependent on WEE1 for survival (a concept called synthetic lethality).
Trial Status
The DENALI Phase 2 trial (Parts 2a, 2b, 2c) is evaluating azenosertib monotherapy in Cyclin E1-positive PROC at the selected 400mg QD 5:2 intermittent dosing schedule. Part 2a/b enrollment is complete; Part 2c is enrolling. The Phase 3 ASPENOVA confirmatory trial has been initiated. DENALI Part 1b interim OS data (15.9 months median OS in Cyclin E1-positive patients) was presented at ESMO Congress 2026. The topline readout from DENALI Part 2 is expected in 1H 2027.
The Two-Sided Case
Upcoming Catalysts
- DENALI Part 2 topline readout expected in 1H 2027 (pivotal efficacy/safety data that could support accelerated approval filing)
- FDA discussions in 2027 regarding accelerated approval pathway
- ASPENOVA Phase 3 confirmatory trial enrollment and interim updates
- Potential expansion data in triple-negative breast cancer and other indications
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Zentalis Pharmaceuticals, Inc. 8-K ZNTL ·Originating report